Basilea at buy by Jefferies

Jefferies & Co., Inc. analyst Robin Campbell rated Basilea Pharmaceutica Inc. at a buy as the company continues to make progress on Ceftobriprole for skin infections. Basilea also plans to file regulatory applications for BAL4079 in 2007 and provide an update on a partnering deal for the IV/oral antifungal product by the end of 2006, according to the analyst. Basilea's first-half results were broadly in line with Jefferies' expectation. Revenues decreased to CHF 3.9 million from CHF 19.5 million in the prior-year period. Shares of the Basel, Switzerland, pharmaceutical company were unchanged at CHF 177.00 on volume of 26,928 shares versus the three-month running average of 7,188 shares. (Swiss: BSLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.